Amarin Corp Plc (AMRN)

[sts66]

"Unfortunately, the loss of patent protection has set a dangerous precedent for the company. There isn't really anything preventing global generic-pharmaceutical companies from challenging Vascepa's patents in other parts of the world (such as in the EU or China), where the drug is currently pending approval by administrative bodies."

Idiot author has no clue how EU drug exclusivity works - there won't be any generic competition in the EU for 10 yrs after V is approved.